insider positions from Toray and  Birch Hill of Toronto

I go back to the management of Meddwell and their keen interest in acquiring ALL the paper they could get as it provided 60% of a DIAGF share for every BioMS share held.

I still think Lilly has a role , as they gave 100M to BioMS that essentially has ALL landed in Spectral's bucket..

Look at the detail around the Eli Lilly solution for Sepsis ( Xigris or Idigris or ? ) and understand many of the players still involved here in the US...

I'll watch out for the $4 target though thanks for the heads up.  

*Anyone know why Birch Hill has NEVER shown EDT as a "investment partner"? :; - )